AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019

Dec 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2019-12-03

Reporting Person: Biller Jonathan (Chief Legal Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-03	Stock option (right to buy)	$39.11	A	78824	Acquired	2029-12-03	Common stock (78824.0)	Direct
2019-12-03	Restricted stock units	$	A	17259	Acquired		Common stock (17259.0)	Direct

Footnotes

F1: This option was granted on December 3, 2019. The shares underlying this option vest as to 25% of the underlying shares on December 3, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.